Plasma components: Properties, differences, and uses

Transfusion

Volumn 52, Issue SUPPL. 1, 2012, Pages

  Benjamin, Richard John ^a   McLaughlin, Lisa Swinton ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; CALCIUM CHLORIDE; CITRIC ACID; CRYOPRECIPITATE POOR PLASMA; DETERGENT; DNA; FIBRINOGEN; FRESH FROZEN PLASMA; GLUCOSE; HLA ANTIBODY; INTERCEPT PLASMA; METHYLENE BLUE; MIRASOL; OCTAPLAS; PHOSPHATE; PLAS+SD PLASMA; POOLED PLASMA PLUS SOLVENT DETERGENT TREATED PLASMA; PSORALEN; RIBOFLAVIN; RNA; SOLVENT; SOYBEAN OIL; THAWED PLASMA; UNCLASSIFIED DRUG; VITAMIN K GROUP; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ARTICLE; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD DONOR; CARDIOPULMONARY BYPASS; CRYOPRECIPITATE; CRYOPRECIPITATION; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PATIENT MONITORING; PATIENT SAFETY; PHLEBOTOMY; PLASMA; PLASMA TRANSFUSION; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; STEM CELL TRANSPLANTATION; SURGICAL PATIENT; THAWING; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT OUTCOME; ULTRAVIOLET IRRADIATION;

BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COMPONENT REMOVAL; BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; HUMANS; PLASMA; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; UNITED STATES;

EID: 84861119185     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03622.x     Document Type: Article

References (60)

1. Spence RK,. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 83-96.
2. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, Gonzalez EA, Pomper GJ, Perkins JG, Spinella PC, Williams KL, Park MS,. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-58.
3. Jabbour N, Gagandeep S, Thomas D, Stapfer M, Mateo R, Sher L, Selby R, Genyk Y,. Transfusion-free techniques in pediatric live donor liver transplantation. J Pediatr Gastroenterol Nutr 2005; 40: 521-3.
4. Ozier Y, Pessione F, Samain E, Courtois F,. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 2003; 97: 671-9.
5. Downes KA, Wilson E, Yomtovian R, Sarode R,. Serial measurement of clotting factors in thawed plasma stored for 5 days [letter]. Transfusion 2001; 41: 570.
6. O'Neill EM, Rowley J, Hansson-Wicher M, McCarter S, Ragno G, Valeri CR,. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999; 39: 488-91.
7. Eder AF, Herron RM, Strupp A, Dy B, White J, Notari EP, Dodd RY, Benjamin RJ,. Effective reduction of TRALI risk with male-predominant plasma strategy in the American Red Cross (2006-8). Transfusion 2010; 50: 1732-42.
8. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ,. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47: 599-607.
9. Kleinman S, Grossman B, Kopko P,. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion 2010; 50: 1312-21.
10. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ,. Solvent/detergent- treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 1999; 94: 3922-7.
11. Prowse C,. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124-33.
12. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L,. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362-72.
13. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L,. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-60.
14. Smith J, Rock G,. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50: 926-31.
15. Smith JF, Ness PM, Moroff G, Luban NL,. Retention of coagulation factors in plasma frozen after extended holding at 1-6 degrees C. Vox Sang 2000; 78: 28-30.
16. Solheim BG, Seghatchian J,. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006; 35: 83-90.
17. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW,. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-31.
18. Rock G,. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-78.
19. Koenigbauer UF, Eastlund T, Day JW,. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40: 1203-6.
20. Hellstern P,. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004; 11: 346-50.
21. Bach J, Haubelt H, Hellstern P,. Sources of variation in factor VIII, von Willebrand factor and fibrinogen measurements: implications for detecting deficiencies and increased plasma levels. Thromb Res 2010; 126: e188-95.
22. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M,. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006; 16: 266-75.
23. Hellstern P, Larbig E, Walz GA, Thurigen W, Oberfrank K,. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionsther Transfusionsmed 1993; 20 Suppl 2: 16-8.
24. Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U,. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993; 4: 599-604.
25. Williamson LM, Llewelyn CA, Fisher NC, Allain JP, Bellamy MC, Baglin TP, Freeman J, Klinck JR, Ala FA, Smith N, Neuberger J, Wreghitt TG,. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 1227-34.
26. Beck KH, Mortelmans Y, Kretschmer V,. Protocol and preliminary results of a clinical study for comparison of solvent/detergent-inactivated plasma VIP versus FFP with special consideration of the balance of hemostasis. Beitr Infusionsther Transfusionsmed 1994; 32: 440-4.
27. Wieding JU, Rathgeber J, Zenjer D,. Prospective, randomized trial and controlled study on solvent detergent versus methylene blue virus inactivated plasma. Transfusion 1999; 39: 23S (abstract).
28. Horowitz B, Pehta JC,. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74 Suppl 1: 231-5.
29. Lerner RG, Nelson J, Sorcia E, Grima K, Kancherla RR, Zarou-Naimo CM, Pehta JC,. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000; 79: 161-7.
30. Mohr H, Lambrecht B, Selz A,. Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24: 73-85.
31. Williamson LM, Cardigan R, Prowse CV,. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43: 1322-9.
32. Wieding JU, Neumeyer H,. [Initial experiences with methylene blue virus inactivated fresh frozen plasma: results of a clinical and in vitro study]. Infusionsther Transfusionsmed 1992; 19: 84-90.
33. Simonsen AC, Sorensen H,. Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers. Vox Sang 1999; 77: 210-7.
34. Ciaravino V, Hanover J, Lin L, Sullivan T, Corash L,. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009; 49: 985-94.
35. Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC,. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50: 1210-9.
36. Cazenave JP,. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety]. Transfus Clin Biol 2011; 18: 53-61.
37. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP,. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15-21.
38. Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP,. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 degrees C. Transfus Apher Sci 2011; 44: 25-31.
39. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP,. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2010; 98: 108-15.
40. Segal JB, Dzik WH,. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-25.
41. Moake JL,. Journey in reverse: TTP from bedside to blood bank to bench. J Clin Apher 2007; 22: 37-49.
42. Moake JL,. The role of von Willebrand factor (vWF) in thrombotic thrombocytopenic purpura (TTP) and the hemolytic-uremic syndrome (HUS). Prog Clin Biol Res 1990; 337: 135-40.
43. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
44. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G,; Canadian Apheresis Group; Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129: 79-86.
45. Rothele E, Krumme B, Rump LC,. Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group. Ther Apher 2000; 4: 327-31.
46. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE,; North American TTP Group. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16: 19-22.
47. Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM,. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999; 21: 119-23.
48. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ,. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121: 778-85.
49. Magner JJ, Crowley KJ, Boylan JF,. Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007; 21: 410-3.
50. Flamholz R, Jeon HR, Baron JM, Baron BW,. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15: 169-72.
51. Atance R, Pereira A, Ramirez B,. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41: 1548-52.
52. Alvarez-Larran A, Del Rio J, Ramirez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre JL, Sanz C, Pereira A,. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86: 246-51.
53. del Rio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castellà D, de la Rubia J, Zamora C, Corral M, Viejo A, Peña F, Rodríguez-Vicente P, Contreras E, Arbona C, Ramírez C, Garcia-Erce JA, Alegre A, Mateo J, Pereira A,. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
54. del Rio-Garma J, Pereira A, Arroyo JL, Mateo J, Alvarez-Larrán A, Martínez C, Muncunill J, Barbolla L,; Spanish Group of Apheresis (Grupo Español de Aféresis GEA). ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an "in house" system. Vox Sang 2008; 95: 101-5.
55. Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A, Mouton-Faivre C,. Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 2011; 106: 687-9.
56. Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N,. Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 2011; 51: 125-8.
57. Cardigan R, Lawrie AS, Mackie IJ, Williamson LM,. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion 2005; 45: 1342-8.
58. McLaughlin LS, Moroff G, Benjamin RJ,. Facilitating blood component preparation: the impact of overnight room temperature storage. Transfusion 2010; 50: 278-80.
59. Thomas S,. Ambient overnight hold of whole blood prior to the manufacture of blood components. Transfus Med 2010; 20: 361-8.
60. Serrano K, Scammell K, Weiss S, Culibrk B, Levin E, Gyöngyössy- Issa M, Devine DV,. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards. Transfusion 2010; 50: 344-53.